Soft Tissue Sarcoma  >>  Torisel (temsirolimus)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

11 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Torisel (temsirolimus) / Pfizer
NCT00087074: CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor

Completed
2
55
US
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, laboratory biomarker analysis
National Cancer Institute (NCI)
Gastrointestinal Stromal Tumor, Recurrent Adult Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
12/05
 
OCR, NCT00743509: A Phase II Study of Oral Cyclophosphamide and Sirolimus () in Advanced Sarcoma

Checkmark Data-ASCO
Jun 2011 - Jun 2011: Data-ASCO
Completed
2
49
US
Cyclophosphamide and Sirolimus, Sirolimus (rapamycin, Rapamune)
University of Michigan Rogel Cancer Center
Osteosarcoma
04/10
09/12
NCT01061606: Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus

Terminated
2
8
US
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel
National Cancer Institute (NCI)
Recurrent Uterine Sarcoma, Uterine Carcinosarcoma
04/12
10/12
NCT01614795: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
46
Canada, US
Cixutumumab, Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12, IMC-A12, Laboratory Biomarker Analysis, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI)
Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma, Childhood Gliosarcoma, Childhood Leiomyosarcoma, Childhood Liposarcoma, Childhood Malignant Peripheral Nerve Sheath Tumor, Childhood Synovial Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Osteosarcoma, Rhabdomyosarcoma
04/14
04/14
NCT01016015: Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma

Checkmark +temsirolimus
Mar 2013 - Mar 2013: +temsirolimus
Checkmark P2 data - ASCO
Jun 2012 - Jun 2012: P2 data - ASCO
Checkmark P2 data
More
Completed
2
178
US, Canada
Cixutumumab, Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12, IMC-A12, Laboratory Biomarker Analysis, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI)
Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Osteosarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
07/14
07/14
NCT01206140: Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
70
US
Laboratory Biomarker Analysis, Selumetinib, ARRY-142886, AZD6244, MEK Inhibitor AZD6244, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI), National Comprehensive Cancer Network
Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
04/15
04/15
NCT01222715: Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
87
US, Canada, RoW
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Laboratory Biomarker Analysis, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Vinorelbine Tartrate, Biovelbin, Eunades, KW-2307, Navelbine, Navelbine Ditartrate, NVB, Vinorelbine Ditartrate
National Cancer Institute (NCI)
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Pleomorphic Rhabdomyosarcoma, Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma
06/15
06/15
NCT01010126: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Checkmark P2 data
More
Completed
2
252
Canada, US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI)
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma, Lung Carcinoid Tumor, Malignant Pancreatic Gastrinoma, Malignant Pancreatic Glucagonoma, Malignant Pancreatic Insulinoma, Malignant Pancreatic Somatostatinoma, Metastatic Digestive System Neuroendocrine Tumor G1, Ovarian Carcinosarcoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Pancreatic Alpha Cell Adenoma, Pancreatic Beta Cell Adenoma, Pancreatic Delta Cell Adenoma, Pancreatic G-Cell Adenoma, Pancreatic Polypeptide Tumor, Recurrent Adult Liver Carcinoma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIA Uterine Corpus Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IIIC Uterine Corpus Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer, Uterine Carcinosarcoma
03/17
03/17
CHONRAD, NCT02008019: A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas

Suspended
2
57
Europe
Everolimus 2.5 mg/day, Afinitor; Votubia; RAD-001, Everolimus 10 mg/day
Centre Leon Berard
Chondrosarcoma
08/18
08/19
NCT00996346: Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas

Checkmark In combination with irinotecan for metastatic sarcoma
Nov 2013 - Nov 2013: In combination with irinotecan for metastatic sarcoma
Terminated
1/2
17
US
Irinotecan&Temsirolimus:Arm1, Level 1, Irinotecan = Camptosar, Campto, or CPT-11, Temsirolimus = Toricel or CCI-779, Irinotecan&Temsirolimus:Arm 1, Level 2, Irinotecan&Temsirolimus:Arm 2, Level 1
New Mexico Cancer Care Alliance, Wyeth is now a wholly owned subsidiary of Pfizer
Sarcoma
11/11
11/13
NCT00949325: Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark Temsirolimus+Liposomal doxorubicin
Feb 2013 - Feb 2013: Temsirolimus+Liposomal doxorubicin
Completed
1/2
24
US
temsirolimus plus liposomal doxorubicin, Torisel, Doxil
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Comprehensive Cancer Network, Wyeth is now a wholly owned subsidiary of Pfizer
Sarcoma
09/12
09/12

Download Options